Nanobiotix

Nanobiotix is a company founded in 2003 headquartered in France. Its most recent tracked round is Series C+. Brouky classifies it under Healthcare & Life Sciences. Brouky records 2 investors associated with the company.

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based nanotherapeutics to revolutionize treatment outcomes for millions of patients with cancer and other challenging diseases. Its lead candidate NBTXR3 is a potential first-in-class radioenhancer designed to increase the dose of radiotherapy absorbed by tumor cells without increasing the dose in surrounding healthy tissues.